Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Stopped Actual sample size of 156 was sufficient to estimate the clinical outcomes.

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

• DRUG: Once-daily aclidinium/formoterol
• DRUG: Twice-daily formoterol fumarate
• DRUG: Placebo to formoterol fumarate
• DRUG: Once-daily formoterol fumarate

Sponsor

AstraZeneca